Natco Pharma stock: Q2 net profit falls 61% to INR 203 crore

Natco Pharma reported a sharp 61% drop in its net profit for the second quarter, falling to INR 203 crore. This decline was primarily driven by a significant reduction in sales of its key anti-cancer drug, Virantra, which faced increased competition in the market. Consequently, the company's revenue from operations also saw a notable contraction during the period.
For investors, this result signals a challenging phase for the company's core oncology business. The drop in profit margins suggests that the firm is currently facing headwinds in maintaining its pricing power amidst a competitive landscape. While the company has a diverse portfolio, this performance highlights the vulnerability of its earnings to the success of its flagship drug.
Moving forward, the market will closely watch how Natco Pharma manages its cost structures and whether it can successfully launch new products to offset the decline in its traditional revenue streams. Investors should also monitor the company's guidance for the upcoming quarters to assess if the current trend is temporary or part of a longer-term structural shift.
Excerpt from ad-hoc-news.de
Natco Pharma reported its September-quarter results for FY27 on Friday, November 13, 2026. According to Business Today , consolidated profit after tax fell to INR 202.6 crore from INR 517.9 crore a year earlier. Consolidated total revenue declined to INR 1,019.4 crore from INR 1,463 crore. Quarterly results point to…Read the original at ad-hoc-news.de
Affected stocks
Bearish1 stockBull / bear label is derived from the article's AI sentiment — indicative, not advice. Prices may be delayed.
Key takeaways
- Concerns Natco Pharma (NATCOPHARM).
- Category: Results.
- AI reads the tone as negative (potentially bearish) for the stock.
Why it matters
A routine update for Natco Pharma. The tone is negative — watch for downside reaction. Use the price and stock snapshot to gauge how the market is responding.




